Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Raanani, Pia ^a   Ben Bassat, I ^b   Gafter Gvili, A ^b   Leibovici, L ^b   Paul, M ^b   Shpilberg, O ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; MORTALITY; OUTCOME ASSESSMENT; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION;

EID: 44949157334     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006501     Document Type: Review

References (38)

1. Abdel-Mageed 1999 Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, Elfenbein GJ, Janiec J, Jansen J, Lazarus HM. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone marrow transplantation 1999;23(9):929- 932.
2. Bass 1993 Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, Wingard JR. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone marrow transplantation 1993;12(3):273-282.
3. Besa 1992 Besa EC. Recent advances in the treatment of chronic lymphocytic leukemia: defining the role of intravenous immunoglobulin. Seminars in hematology 1992;29(3 Suppl 2):14-23.
4. Bowden 1986 Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD. ytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. The New England journal of medicine 1986;314(16): 1006-1010.
5. Chapel 1994a Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phasemultiplemyeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994;343(8905):1059-1063.
6. Chapel 1994b Chapel HM, Lee M. The use of intravenous immune globulin in multiple myeloma. Clinical and experimental immunology 1994;97 Suppl 1:21-24.
7. Condie 1984 Condie RM, O'Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. The American journal of medicine 1984;76(3A):134-141.
8. Consensus IVIG 1990 No authors listed. Consensus on IVIG. Lancet 1990;336(8713):470-472.
9. Cordonnier 2003 Cordonnier C, Chevret S, Legrand M, Rafi H, Dhedin N, Lehmann B, Bassompierre F, Gluckman E. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Annals of internal medicine 2003;139(1):8-18.
10. Espersen 1984 Espersen F, Birgens HS, Hertz JB, Drivsholm A. Current patterns of bacterial infection inmyelomatosis. Scandinavian journal of infectious diseases 1984;16(2):169-173.
11. Fairley 1961 Fairley GH, Scott RB. Hypogammaglobulinaemia in chronic lymphatic leukaemia. British medical journal 1961;5257: 920-924.
12. Glowacki 1993 Glowacki LS, Smaill FM. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease. Transplantation proceedings 1993;25(1 Pt 2):1408-1410.
13. Glowacki 1994 Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a meta-analysis. Clinical transplantation 1994;8(1):10-18.
14. Graham-Pole 1988 Graham-Pole J, Camitta B, Casper J, Elfenbein G, Gross S, Herzig R, Koch P, Mahoney D, Marcus R, Munoz L. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone marrow transplantation 1988;3(6):559-566.
15. Guglielmo 1994 Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bonemarrow transplant: a critical review. Bonemarrow transplantation 1994;13(5):499-510.
16. Hansen 1973 Hansen MM. Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time. Scandinavian journal of haema-tology. Supplementum 1973;18:3-286.
17. Jim 1956 Jim RT, Reinhard EH. Agammaglobulinemia and chronic lymphocytic leukemia. Annals of internal medicine 1956;44(4):790- 796.
18. Jurlander 1994 Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. European journal of haematology 1994;53(2):114-118.
19. Nasman 1999 Nasman B, I, Fesel C, Brissac C, Lundkvist I. Prophylactic intravenous immunoglobulin treatment influences serum immunoglobulin M repertoire development after allogeneic bone marrow transplantation. Scandinavian journal of immunology 1999;50(1):73- 82.
20. Perri 1981 Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. The American journal of medicine 1981;71(6):935-940.
21. Petersen 1987 Petersen FB, Bowden RA, Thornquist M, Meyers JD, Buckner CD, Counts GW, Nelson N, Newton BA, Sullivan KM, McIver J. The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone marrow transplantation 1987;2(2):141-147.
22. Pirofsky 1984 Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia. A review. The American journal of medicine 1984;76(3A):53-60.
23. Rozman 1988 Rozman C, Montserrat E, Vinolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer 1988;61(2):279-283.
24. Ruutu 1997 Ruutu T, Ljungman P, Brinch L, Lenhoff S, Lonnqvist B, Ringden O, Ruutu P. Volin L, Albrechtsen D, Sallerfors B, Ebeling F, Myllyla G. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone marrow transplantation 1997;19(3):233-236.
25. Savage 1982 Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Annals of internal medicine 1982;96(1):47-50.
26. Siadak 1994 Siadak MF, Kopecky K, Sullivan KM. Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. Clinical and experimental immunology 1994;97(Suppl 1):53-57.
27. Sokos 2002 Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002;8(3):117- 130.
28. Sullivan 1990 Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. The New England journal of medicine 1990;323(11):705-712.
29. Sullivan 1996 Sullivan KM. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clinical and experimental immunology 1996;104 Suppl 1:43-48.
30. Twomey 1973 Twomey JJ. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Archives of internal medicine 1973;132(4):562-565.
31. Wingard 1990 Wingard JR. Advances in the management of infectious complications after bone marrow transplantation. Bone marrow transplantation 1990;6(6):371-383.
32. Winston 1987a Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Annals of internalmedicine 1987;106(1):12-18.
33. Winston 1987b Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Annals of internalmedicine 1987;106(1):12-18.
34. Winston 1990 Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Reviews of infectious diseases 1990;12 Suppl 7:S776-S792.
35. Winston 1993 Winston DJ, Ho WG, Bartoni K, Champlin RE. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone marrow transplantation 1993;12(3):283-288.
36. Winston 2001 Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone marrow transplantation 2001;28(2):187-196.
37. Wittes 1996 Wittes JT, Kelly A, Plante KM. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplantation proceedings 1996;28(6 Suppl 2):17-24.
38. Wolff 1993 Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, Collins RH, Stevens DA, Herzig GP. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Annals of internal medicine 1993;118(12):937-942.